Invivyd, Inc.

IVVD

Healthcare Biotechnology

Invivyd, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.4 million, up 110.5% from fiscal 2024.

Revenue
+21.2%
EPS
−16.7%
Free cash flow
−226.9%

Quarter to June 2026, against a year earlier

0.56 0.03 −5.08%
Market cap
$166.0M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
n/a
ROIC
−334.9%
Net debt / EBITDA
4.2×
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '17
P/E ratio
0.00 0.00 — — — — —
P/S ratio
7.96 0.00 — — — — —
Altman Z-Score
2.85 (13.19) — — — — —
P/FCF ratio
0.00 0.00 — — — — —
Altman Z″-Score (non-manufacturers)
(0.36) (28.78) — — — — —
Beneish M-Score
(1.63) — — — — — —
P/Operating CF
(27.52) (1.39) — — — — —
P/B ratio
1.76 0.77 — — — — —
EV/Sales
3.72 0.00 — — — — —
EV/EBITDA
0.00 0.10 — — — — —
EV/FCF
(3.41) 0.10 — — — — —
Current Ratio
7.24 1.62 4.47 15.06 9.94 8.98 —
Net Debt/EBITDA
4.24 0.40 0.95 1.49 2.62 1.76 —
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 —
ROE
(33.96%) (138.71%) (74.48%) (52.81%) (92.05%) (26.51%) —
ROA
(25.83%) (94.75%) (64.88%) (48.11%) (61.50%) (111.29%) —
ROIC
(233.82%) 0.00% 0.00% 0.00% 0.00% 0.00% —
Return on Tangible Assets
(24.45%) (422.56%) (112.55%) (68.14%) (40.88%) (62.62%) —
Average Days of Receivables
95.09 156.82 — 0.00 — — —
Earnings Yield
(12.96%) (327.27%) — — — — —
Free Cash Flow Yield
(13.70%) (327.10%) — — — — —
Free Cash Flow per Share
(0.34) (1.44) (1.59) (2.05) (4.34) (4.04) —
Book value per Share
1.40 0.57 1.62 3.29 13.09 (18.08) —
Free Cash Flow
(58.29) (170.63) (173.78) (221.69) (184.82) (14.57) —
EV/EBIT
0.00 0.10 — — — — —
Other line items

Show all line items

Columns are period end dates